Top-News

FUTR holt sich eine KI-Legende aus der Luft- und Raumfahrt - das Spiel hat sich für immer verändert(Anzeige)

Ein Arzt berät einen Patienten (Symbolbild).

Quelle: © TommL / Vetta / Getty Images: www.gettyimages.de

PR Newswire | 12. August 2025, 06:55

Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

PR Newswire

Anhören

Aufhören

Feedback

Kopieren

Schrift vergrößern

Schrift verkleinern

Cardinal Health Inc 198,87 $

-0,16%

Zugehörige Wertpapiere:

DUBLIN, Ohio, Aug. 12, 2025

Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expiration
Fourth quarter GAAP¹ operating earnings were $428 million and GAAP diluted EPS was $1.00
Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08
Fiscal Year 2025 adjusted free cash flow was $2.5 billion
Fiscal year 2026 non-GAAP EPS guidance² raised to $9.30 to $9.50, from $9.10 to $9.30
Company announces the acquisition of Solaris Health, the country's leading urology MSO

DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2025 revenues of $60.2 billion, relatively flat to the fourth quarter of fiscal year 2024. Fourth quarter revenue increased 21% excluding the impact of a previously communicated customer contract expiration. GAAP operating earnings were $428 million and GAAP diluted earnings per share (EPS) were $1.00. Non-GAAP operating earnings increased 19% to $719 million, driven by segment profit increases across Pharmaceutical and Specialty Solutions, GMPD and Other³. Non-GAAP diluted EPS increased 13% to $2.08 in the quarter, reflecting the increase in non-GAAP operating earnings and a lower share count, partially offset by an increase in interest and other expense due to financing costs related to recent acquisitions and a higher non-GAAP effective tax rate.

Fiscal year 2025 revenues were $222.6 billion, a 2% decrease from fiscal year 2024. Fiscal year 2025 revenue increased 18% excluding the impact of a previously communicated customer contract expiration. GAAP operating earnings were $2.3 billion and GAAP diluted EPS was $6.45. Non-GAAP operating earnings increased 15% to $2.8 billion, driven primarily by segment profit increases in Pharmaceutical and Specialty Solutions and Other. Non-GAAP diluted EPS increased 9% to $8.24 for the year, reflecting the increase in non-GAAP operating earnings across the business and a lower share count following in-year share repurchases, partially offset by higher interest and other expense and a higher non-GAAP effective tax rate.

"Fiscal 2025 was a transformative year for Cardinal Health, and we closed the year with momentum, delivering strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health. "The broad-based operational strength, with all five of our operating segments growing profit double-digits, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2026 with confidence, evidenced by our increased financial outlook, as we continue to evolve towards reaching our full potential."

Q4 and full year FY25 summary

	Q4 FY25	Q4 FY24	Y/Y	FY25	FY24	Y/Y
Revenue	$60.2 billion	$59.9 billion	— %	$222.6 billion	$226.8 billion	(2) %
Operating earnings	$428 million	$401 million	7 %	$2.3 billion	$1.2 billion	83 %
Non-GAAP operating earnings	$719 million	$605 million	19 %	$2.8 billion	$2.4 billion	15 %
Net earnings attributable to Cardinal Health, Inc.	$239 million	$235 million	2 %	$1.6 billion	$852 million	83 %
Non-GAAP net earnings attributable to Cardinal Health, Inc.	$501 million	$450 million	11 %	$2.0 billion	$1.9 billion	7 %
Effective Tax Rate	36.9 %	40.4 %		25.3 %	28.9 %
Non-GAAP Effective Tax Rate	26.3 %	24.6 %		23.3 %	21.7 %
Diluted EPS attributable to Cardinal Health, Inc.	$1.00	$0.96	4 %	$6.45	$3.45	87 %
Non-GAAP diluted EPS attributable to Cardinal Health, Inc.	$2.08	$1.84	13 %	$8.24	$7.53	9 %

Segment results

Pharmaceutical and Specialty Solutions segment

	Q4 FY25	Q4 FY24	Y/Y	FY25	FY24	Y/Y
Revenue	$55.4 billion	$55.6 billion	— %	$204.6 billion	$210.0 billion	(3) %
Segment profit	$535 million	$482 million	11 %	$2.3 billion	$2.0 billion	12 %

Fourth-quarter revenue for the Pharmaceutical and Specialty Solutions segment was relatively flat at $55.4 billion. Fourth-quarter revenue increased 22% excluding the impact of the customer contract expiration, driven by brand and specialty pharmaceutical sales growth from existing and new customers.

Pharmaceutical and Specialty Solutions segment profit increased 11% to $535 million in the fourth quarter, driven by the acquisition of MSO platforms and contributions from brand and specialty products, partially offset by the customer contract expiration.

Global Medical Products and Distribution segment

	Q4 FY25	Q4 FY24	Y/Y	FY25	FY24	Y/Y
Revenue	$3.2 billion	$3.1 billion	3 %	$12.6 billion	$12.4 billion	2 %
Segment profit	$70 million	$47 million	49 %	$135 million	$92 million	47 %

Fourth-quarter revenue for the Global Medical Products and Distribution segment increased 3% to $3.2 billion, driven by volume growth from existing customers.

Global Medical Products and Distribution segment profit increased 49% to $70 million in the fourth quarter, driven by volume growth from existing customers.

Other³

	Q4 FY25	Q4 FY24	Y/Y	FY25	FY24	Y/Y
Revenue	$1.6 billion	$1.2 billion	37 %	$5.4 billion	$4.5 billion	19 %
Segment profit	$160 million	$111 million	44 %	$516 million	$423 million	22 %

Fourth-quarter revenue for Other increased 37% to $1.6 billion, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics.

Other segment profit increased 44% to $160 million in the fourth quarter, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics.

Fiscal year 2026 outlook²The company raised its fiscal year 2026 outlook for non-GAAP diluted EPS to $9.30 to $9.50 (+13% to +15% growth), a $0.20 increase from the preliminary outlook of $9.10 to $9.30 previously communicated during the company's 2025 Investor Day.

Non-GAAP earnings per share	$9.30 to $9.50
Pharmaceutical and Specialty Solutions segment:
Revenue	11% to 13% growth
Segment profit	11% to 13% growth
Global Medical Products and Distribution segment:
Revenue	2% to 4% growth
Segment profit	At least $140 million
Other (NPHS, at-Home Solutions, OptiFreight Logistics):
Revenue	26% to 28% growth
Segment profit	25% to 27% growth
Interest and other	~$275 million
Non-GAAP effective tax rate	22.0% - 24.0%
Diluted weighted average shares outstanding	238 million to 240 million
Share repurchases	~$750 million
Capital Expenditures	~$600 million
Non-GAAP adjusted free cash flow	$2.75 billion to $3.25 billion

Bold indicates a change to the preliminary FY26 outlook provided in the Investor Day press release on June 12, 2025.

The increase to non-GAAP diluted EPS reflects a benefit to net earnings of classifying the shares held by physicians and management of The Specialty Alliance as a liability as opposed to non-controlling interests within equity and increased contributions from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in Other.³

Recent highlights

Cardinal Health hosted an Investor Day on June 12th, 2025 where management detailed the company's momentum, growth strategies and updated long-term value creation plans
Cardinal Health announced that the company entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO with over 750 providers. Solaris Health will join the Specialty Alliance's Urology Alliance and advances Cardinal Health's multi-specialty growth strategy
Cardinal Health hosted its 33^rd annual Retail Business Conference, bringing together approximately 5,000 attendees from across the country to celebrate the critical role its independent pharmacy customers play in caring for their communities and highlight the company's innovations and commitment to its customers
Cardinal Health announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts
Cardinal Health announced the U.S. launch of Kendall DL™ Multi System, its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection
Cardinal Health released its inaugural cell and gene therapy industry report providing insights into the current landscape and promising potential of cell and gene therapies
The Cardinal Health Foundation expanded its Equity Rx program across Ohio and three new states, increasing access to affordable medications and supporting Ohio's first statewide prescription drug repository

Webcast
Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss fourth quarter and full year results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.

Presentation slides and a webcast replay will be available until August 13, 2026.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.

Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and 614.757.8231
Investors: Matt Sims, matt.sims@cardinalhealth.com and 614.553.3661

¹GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

²The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

³Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions concerning forward-looking statements
This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include the risk that we may fail to achieve our strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives, whether as a result of tariffs on products we source or manufacture, an uncertain global economic and trade environment, Cardinal Health Brand sales or ongoing inflationary pressures; our ability to manage uncertainty with respect to certain government initiatives, including the Executive Order regarding "Most Favored Nation" pricing for branded prescription pharmaceuticals and the One Big Beautiful Bill Act; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, may impact demand for our products or may cause supply shortages that impact our cost and ability to fulfill customer demand; the performance of our generics program, including our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs; risks associated with recently completed and pending acquisitions, including risks arising as a result from our entry into new lines of businesses. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of August 12, 2025. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com

Schedule 1
Cardinal Health, Inc. and Subsidiaries Consolidated Statements of Earnings (Unaudited)

	Fourth Quarter			Fiscal Year
(in millions, except per common share amounts)	2025	2024	% Change	2025	2024	% Change
Revenue	$ 60,159	$ 59,867	— %	$ 222,578	$ 226,827	(2) %
Cost of products sold	57,957	57,985	— %	214,410	219,413	(2) %
Gross margin	2,202	1,882	17 %	8,168	7,414	10 %

Operating expenses:
Distribution, selling, general and administrative expenses	1,484	1,277	16 %	5,382	5,000	8 %
Restructuring and employee severance	27	69		88	175
Amortization and other acquisition-related costs	133	77		464	284
Acquisition-related cash and share-based compensation costs	106	—		126	—
Impairments and (gain)/loss on disposal of assets, net ¹	33	8		18	634
Litigation (recoveries)/charges, net	(9)	50		(185)	78
Operating earnings	428	401	7 %	2,275	1,243	83 %

Other (income)/expense, net	(30)	1		(41)	(9)
Interest expense, net	74	9	N.M.	215	51	N.M.
Earnings before income taxes	384	391	(2) %	2,101	1,201	75 %

Provision for income taxes ²	141	158	(11) %	532	348	53 %
Net earnings	243	233	4 %	1,569	853	84 %

Less: Net (earnings)/loss attributable to noncontrolling interests	(4)	2		(8)	(1)
Net earnings attributable to Cardinal Health, Inc.	$ 239	$ 235	2 %	$ 1,561	$ 852	83 %

Earnings per common share attributable to Cardinal Health, Inc.:
Basic	$ 1.01	$ 0.96	5 %	$ 6.48	$ 3.48	86 %
Diluted	1.00	0.96	4 %	6.45	3.45	87 %

Weighted-average number of common shares outstanding:
Basic	239	244		241	245
Diluted	240	245		242	247

¹Impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $675 million related to the GMPD segment recorded in fiscal year ended June 30, 2024.

²Provision for income taxes includes the tax effects relating to the cumulative goodwill impairment charges. For fiscal 2024, the net tax benefits related to the goodwill impairment charges was $58 million.

Schedule 2
Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)

(in millions)	June 30, 2025	June 30, 2024
Assets
Current assets:
Cash and equivalents	$ 3,874	$ 5,133
Trade receivables, net	13,242	12,084
Inventories, net	16,831	14,957
Prepaid expenses and other	2,414	2,663
Assets held for sale	12	47
Total current assets	36,373	34,884

Property and equipment, net	2,858	2,529
Goodwill and other intangibles, net	12,177	6,450
Other assets	1,714	1,258
Total assets	$ 53,122	$ 45,121

Liabilities and Shareholders' Deficit
Current liabilities:
Accounts payable	$ 34,713	$ 31,759
Current portion of long-term obligations and other short-term borrowings	550	434
Other accrued liabilities	3,634	3,447
Total current liabilities	38,897	35,640

Long-term obligations, less current portion	7,977	4,658
Deferred income taxes and other liabilities	8,882	8,035

Total shareholders' deficit	(2,634)	(3,212)
Total liabilities and shareholders' deficit	$ 53,122	$ 45,121

Schedule 3
Cardinal Health, Inc. and Subsidiaries Consolidated Statements of Cash Flows (Unaudited)

	Fourth Quarter		Fiscal Year
(in millions)	2025	2024	2025	2024
Cash flows from operating activities:
Net earnings	$ 243	$ 233	$ 1,569	853

Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	209	186	790	710
Impairments and loss on sale of other investments	1	2	3	2
Impairments and (gain)/loss on disposal of assets, net	33	8	18	634
Share-based compensation	153	33	244	121
Provision for/(benefit from) deferred income taxes	243	(104)	243	(104)
Provision for bad debts	12	8	53	36
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables	(466)	(773)	(833)	(996)
(Increase)/decrease in inventories	(607)	2,373	(1,816)	1,115
Increase/(decrease) in accounts payable	1,778	(294)	2,732	1,824
Other accrued liabilities and operating items, net	(72)	410	(606)	(433)
Net cash provided by operating activities	1,527	2,082	2,397	3,762

Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired	(1,395)	2	(5,250)	(1,190)
Additions to property and equipment	(232)	(193)	(547)	(511)
Proceeds from net investment hedge terminations	—	6	2	34
Purchase of short-term time deposits	—	—	—	(550)
Proceeds from short-term investment in time deposit	—	350	200	350
Other investing items, net	(4)	1	2	18
Net cash provided by/(used in) investing activities	(1,631)	166	(5,593)	(1,849)

Cash flows from financing activities:
Proceeds from long-term obligations, net of issuance costs	800	—	3,669	1,139
Purchases and payments of noncontrolling interests, net	(12)	—	(12)	—
Reduction of long-term obligations	(11)	(760)	(445)	(783)
Net tax proceeds from share-based compensation	(1)	23	(13)	46
Dividends on common shares	(120)	(122)	(494)	(499)
Purchase of treasury shares	—	—	(765)	(750)
Net cash provided by/(used in) financing activities	656	(859)	1,940	(847)

Effect of exchange rates changes on cash and equivalents	(4)	(2)	(3)	(9)

Net increase/(decrease) in cash and equivalents	548	1,387	(1,259)	1,057
Cash and equivalents at beginning of period	3,326	3,746	5,133	4,076
Cash and equivalents at end of period	$ 3,874	$ 5,133	$ 3,874	$ 5,133

Schedule 4
Cardinal Health, Inc. and Subsidiaries Segment Information (Unaudited)

	Fourth Quarter

	Pharmaceutical and Specialty Solutions		Global Medical Products and Distribution		Other
(in millions)	2025	2024	2025	2024	2025	2024
Revenue
Amount	$ 55,372	$ 55,608	$ 3,199	$ 3,109	$ 1,609	$ 1,172
Growth rate	— %	13 %	3 %	2 %	37 %	15 %

Segment profit
Amount	$ 535	$ 482	$ 70	$ 47	$ 160	$ 111
Growth rate	11 %	8 %	49 %	N.M.	44 %	11 %
Segment profit margin	0.97 %	0.87 %	2.19 %	1.51 %	9.94 %	9.47 %

	Fiscal Year

	Pharmaceutical and Specialty Solutions		Global Medical Products and Distribution		Other
(in millions)	2025	2024	2025	2024	2025	2024
Revenue
Amount	$ 204,644	$ 210,019	$ 12,636	$ 12,381	$ 5,382	$ 4,512
Growth rate	(3) %	11 %	2 %	1 %	19 %	12 %

Segment profit
Amount	$ 2,258	$ 2,015	$ 135	$ 92	$ 516	$ 423
Growth rate	12 %	7 %	47 %	N.M.	22 %	7 %
Segment profit margin	1.10 %	0.96 %	1.07 %	0.74 %	9.59 %	9.38 %

The sum of the components and certain computations may reflect rounding adjustments.

Schedule 5
Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation¹(Unaudited)

									Net
									(Earnings)/
									Loss
		Gross				Operating	Earnings	Provision	Attributable		Net			Diluted
		Margin		SG&A²		Earnings	Before	for	to Non-		Earnings³	Effective		EPS ³
(in millions, except per common share amounts)	Gross	Growth		Growth	Operating	Growth	Income	Income	Controlling	Net	Growth	Tax	Diluted	Growth
	Margin	Rate	SG&A ²	Rate	Earnings	Rate	Taxes	Taxes	Interests	Earnings³	Rate	Rate	EPS ³	Rate
	Fourth Quarter 2025
GAAP	$ 2,202	17 %	$ 1,484	16 %	$ 428	7 %	$ 384	$ 141	$ (4)	$ 239	2 %	36.9 %	$ 1.00	4 %
Restructuring and employee severance	—		—		27		27	6	—	21			0.09
Amortization and other acquisition-related costs	—		—		133		133	23	2	112			0.46
Acquisition-related cash & share-based compensation costs	—		—		106		106	1	4	109			0.45
Impairments and (gain)/loss on disposal of assets, net	—		—		33		33	9	—	24			0.10
Litigation (recoveries)/charges, net	—		—		(9)		(9)	(2)	—	(7)			(0.03)
Non-GAAP	$ 2,203	17 %	$ 1,484	16 %	$ 719	19 %	$ 676	$ 178	$ 3	$ 501	11 %	26.3 %	$ 2.08	13 %

	Fourth Quarter 2024
GAAP	$ 1,882	5 %	$ 1,277	2 %	$ 401	N.M.	$ 391	$ 158	$ 2	$ 235	N.M.	40.4 %	$ 0.96	N.M.
Restructuring and employee severance	—		—		69		69	13	—	56			0.23
Amortization and other acquisition-related costs	—		—		77		77	19	—	58			0.24
Impairments and (gain)/loss on disposal of assets, net ⁴	—		—		8		8	(32)	—	40			0.16
Litigation (recoveries)/charges, net	—		—		50		50	(12)	—	62			0.25
Non-GAAP	$ 1,882	5 %	$ 1,277	2 %	$ 605	14 %	$ 595	$ 147	$ 2	$ 450	23 %	24.6 %	$ 1.84	29 %

¹For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

²Distribution, selling, general and administrative expenses.

³Attributable to Cardinal Health, Inc.

⁴During fiscal 2024, we recorded cumulative pre-tax goodwill impairment charges of $675 million related to GMPD in impairments and (gain)/loss on disposal of assets, net. The estimated net tax benefit related to the impairments is $58 million and is included in the annual effective tax rate. During the three months ended June 30, 2024, the amount of tax expense recognized related to goodwill impairment charges was $34 million, which reflects the reversal of the incremental tax benefit recognized during the nine months ended March 31, 2024.

The sum of the components and certain computations may reflect rounding adjustments.

We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Schedule 5

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation¹(Unaudited)

Net

Earnings

Gross

Operating

Earnings

Provision

Attributable

Net

Diluted

Margin

SG&A²

Earnings

Before

for

to Non-

Earnings³

Effective

EPS ³

Gross

Growth

Operating

Growth

Income

Controlling

Net

Growth

Tax

Diluted

Growth

(in millions, except per common share amounts)

Margin

Rate

SG&A ²

Rate

Earnings

Rate

Taxes

Interests

Earnings³

Rate

EPS ³

Rate

Fiscal Year 2025

GAAP

$ 8,168

10 %

$ 5,382

8 %

$ 2,275

83 %

$ 2,101

$ 532

$ (8)

$ 1,561

83 %

25.3 %

$ 6.45

87 %

Restructuring and employee severance

—

0.28

Amortization and other acquisition-related costs

—

464

104

—

360

1.49

Acquisition-related cash & share-based compensation costs

—

126

—

125

0.51

Impairments and (gain)/loss on disposal of assets, net

—

0.05

Litigation (recoveries)/charges, net

—

(185)

(54)

—

(131)

(0.54)

Non-GAAP

$ 8,168

10 %

$ 5,382

8 %

$ 2,786

15 %

$ 2,612

$ 609

$ (8)

$ 1,995

7 %

23.3 %

$ 8.24

9 %

Fiscal Year 2024

GAAP

$ 7,414

8 %

$ 5,000

4 %

$ 1,243

65 %

$ 1,201

$ 348

$ (1)

$ 852

Für dich aus unserer Redaktion zusammengestellt

Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

Für dich aus unserer Redaktion zusammengestellt

Dein Kommentar zum Artikel im Forum

Weitere Artikel des Autors

Themen im Trend

Themen im Trend

Neueste News

Meistgesuchte Aktien auf Ariva.de